MainboardGMP — Live IPO Grey Market Premium | NSE BSE GMP Tracker India
MainboardGMP
LIVE
LIVE GMP
Watrana Rentals Ltd₹+65·Mahanadi Coalfields Ltd₹0·Integris Medtech₹0·Foodlink F&B Holdings (India)₹+12·Shree Siddhivinayak Greentech Industries₹0·Crystal Crop Protection Ltd₹+14·Vedant Poly Fabs Ltd₹0·Johnsoncab Electricals Ltd₹+5·HGS (India) Ltd₹+38·Vectras Enprocon Ltd₹0·Maxwell Engineering Solutions Ltd₹+82·Antala Industries Ltd₹0·Bombay Coated & Special Steels Ltd₹+8·Carver Roboweld Ltd₹0·Ajwa Projects Ltd₹0·Watrana Rentals Ltd₹+65·Mahanadi Coalfields Ltd₹0·Integris Medtech₹0·Foodlink F&B Holdings (India)₹+12·Shree Siddhivinayak Greentech Industries₹0·Crystal Crop Protection Ltd₹+14·Vedant Poly Fabs Ltd₹0·Johnsoncab Electricals Ltd₹+5·HGS (India) Ltd₹+38·Vectras Enprocon Ltd₹0·Maxwell Engineering Solutions Ltd₹+82·Antala Industries Ltd₹0·Bombay Coated & Special Steels Ltd₹+8·Carver Roboweld Ltd₹0·Ajwa Projects Ltd₹0·
All Articles
IPO Education

Encube Ethicals IPO 2026: DRHP, Issue Size, GMP & Latest Updates

Published: 18 Nov 2026 Last Updated: 22 Nov 2026 13 min read MainboardGMP Research Desk 37 views
Cover image for: Encube Ethicals IPO 2026: DRHP, Issue Size, GMP & Latest Updates

Encube Ethicals IPO is attracting attention from investors interested in India's pharmaceutical manufacturing and contract development and manufacturing organisation (CDMO) sector. Encube Ethicals Limited is an Indian pharmaceutical company specialising in topical and transdermal formulations, including creams, ointments, gels, lotions and other pharmaceutical products for domestic and international markets.

The proposed IPO could provide investors with an opportunity to explore the company's business model, manufacturing capabilities, financial performance and growth prospects. The company has proposed a public issue of up to ₹3,000 crore through an Offer for Sale (OFS), in which existing shareholders will sell their shares to public investors.

Encube Ethicals has filed its Draft Red Herring Prospectus (DRHP) with SEBI, and SEBI observations have been issued on the proposed IPO documents. However, the IPO opening date, price band, lot size and listing schedule are yet to be officially announced. Investors should review the company's financial position, business risks and final offer documents before making an investment decision.


Encube Ethicals IPO Overview

Encube Ethicals Limited is preparing to enter the public market through its proposed Initial Public Offering. The company operates in the pharmaceutical manufacturing industry, with a focus on topical medicines, generic formulations and contract manufacturing services.

The proposed IPO is structured as an Offer for Sale, meaning existing shareholders will sell their shares to public investors. The company will not receive proceeds from the OFS for business expansion or other corporate requirements.


Encube Ethicals IPO Details

IPO Particulars

Details

Company Name

Encube Ethicals Limited

IPO Type

Mainboard IPO

Issue Type

Book-built issue

DRHP Filing Date

August 1, 2026

Total Issue Size

Up to ₹3,000 crore

Fresh Issue

Nil

Offer for Sale (OFS)

Up to ₹3,000 crore

Face Value

₹1 per equity share

Promoter Selling Shareholder

Mehul Madhusudan Shah

Investor Selling Shareholder

Frontier Investment Holdings Pte. Ltd.

Promoter OFS

Up to ₹2,000 crore

Investor OFS

Up to ₹1,000 crore

IPO Opening Date

Not announced

IPO Closing Date

Not announced

Price Band

Not announced

Lot Size

Not announced

Listing Exchanges

NSE and BSE

Registrar

MUFG Intime India Pvt. Ltd.

The proposed IPO is entirely an Offer for Sale. Mehul Madhusudan Shah, the promoter selling shareholder, plans to sell shares worth up to ₹2,000 crore, while Frontier Investment Holdings Pte. Ltd. proposes to sell shares worth up to ₹1,000 crore.

Since the issue does not include a fresh issue of shares, Encube Ethicals will not receive the money raised through the IPO. The proceeds will go to the selling shareholders, subject to transaction-related expenses and applicable taxes.


Encube Ethicals IPO Latest Update

Encube Ethicals Limited filed its Draft Red Herring Prospectus (DRHP) with SEBI on August 1, 2026, for its proposed ₹3,000 crore IPO. The company plans to list its shares on the Indian stock exchanges through an OFS.

On November 4, 2026, SEBI issued its observations on the company's IPO documents. This is an important step in the IPO process, allowing the company to move towards the next stage of preparation, including filing the Red Herring Prospectus and finalising the issue terms.

However, the IPO opening date, price band, lot size and subscription schedule have not yet been officially announced. Investors should wait for the company's final offer documents for confirmed information.

SEBI observations do not mean that the IPO is guaranteed to open on a particular date or that investors should subscribe.


About Encube Ethicals Limited

Encube Ethicals Limited is an Indian pharmaceutical company focused on the development and manufacturing of topical and transdermal pharmaceutical products. The company produces medicines in dosage forms such as creams, ointments, gels, lotions, sprays and patches.

Its business covers pharmaceutical formulations, generic medicines, contract manufacturing and branded products. Encube serves customers in India and international markets, making it a company with exposure to both domestic pharmaceutical demand and overseas healthcare markets.

The company has built its business around pharmaceutical manufacturing expertise, product development, research capabilities and regulatory compliance. Its products are supplied to various pharmaceutical companies and markets, where quality standards, manufacturing consistency and regulatory approvals play an important role.

Encube Ethicals was originally incorporated in 1995 and has developed its manufacturing and product portfolio over the years.


What Does Encube Ethicals Do?

Encube Ethicals operates in the pharmaceutical manufacturing industry, with a focus on topical and transdermal formulations.

1. Global Generics

Encube manufactures generic pharmaceutical products for international markets. Generic medicines contain active pharmaceutical ingredients equivalent to those in reference medicines, subject to applicable regulatory and quality requirements.

The company's manufacturing and formulation capabilities help it serve pharmaceutical customers in international markets.

2. Contract Development and Manufacturing (CDMO)

The company also works with pharmaceutical businesses through contract development and manufacturing services.

Under the CDMO model, pharmaceutical companies can outsource product development, formulation work and manufacturing to specialised companies. This allows clients to utilise external manufacturing infrastructure and technical expertise rather than establishing all production capabilities themselves.

Encube's CDMO business serves pharmaceutical clients seeking manufacturing and development support for topical products.

3. India Branded Pharmaceutical Business

Encube also has a presence in the Indian pharmaceutical market through branded products.

Its portfolio includes established brands such as Soframycin. Branded medicines allow the company to participate in the domestic pharmaceutical market through product recognition, distribution and healthcare demand.


Encube Ethicals IPO Issue Size and OFS Structure

The proposed Encube Ethicals IPO is worth up to ₹3,000 crore and consists entirely of an Offer for Sale.

Selling Shareholder

Proposed OFS Value

Mehul Madhusudan Shah

₹2,000 crore

Frontier Investment Holdings Pte. Ltd.

₹1,000 crore

Total OFS

₹3,000 crore


What Does an OFS Mean for Investors?

An Offer for Sale is a process in which existing shareholders sell their shares to the public through an IPO.

Unlike a fresh issue, the company does not receive the money raised from these shares. The proceeds go to the selling shareholders, subject to transaction expenses and applicable taxes.

Therefore, Encube Ethicals' proposed IPO is primarily a liquidity event for its existing shareholders rather than a capital-raising exercise for the company.

Investors should note that the IPO proceeds will not directly be available to Encube for setting up new manufacturing facilities, expanding production capacity, funding new research and development, repaying company borrowings or financing day-to-day business operations.

It is therefore important to assess the company's existing financial position, growth plans and operating performance separately from the IPO proceeds.


Encube Ethicals Financial Performance

Encube Ethicals has reported growth in revenue and profitability over the last three financial years. The company's financial performance is an important factor for investors evaluating its proposed IPO, particularly because the issue is an OFS and the company itself will not receive IPO proceeds.

According to its reported consolidated financial information, Encube Ethicals recorded growth in revenue, EBITDA and profit after tax between FY24 and FY26.

Revenue from Operations

Revenue from operations represents the income generated from the company's primary business activities, including pharmaceutical manufacturing, product sales and contract manufacturing services.

Financial Year

Revenue from Operations

FY24

₹1,085.90 crore

FY25

₹1,344.80 crore

FY26

₹1,848.70 crore

The company recorded an increase in revenue from ₹1,085.90 crore in FY24 to ₹1,848.70 crore in FY26. This growth reflects an expansion in its business operations and pharmaceutical manufacturing activities.


EBITDA Performance

EBITDA is an indicator of operating profitability before interest, taxes, depreciation and amortisation. It helps investors understand how efficiently a company generates earnings from its operations.

Financial Year

EBITDA

FY24

₹297.60 crore

FY25

₹452.10 crore

FY26

₹663.30 crore

Encube's EBITDA increased during the reported period, while its EBITDA margin also improved. Higher operating earnings and improved margins may indicate stronger operating performance, although investors should also evaluate cash flows, working capital requirements and other financial obligations.


Profit After Tax (PAT)

Profit after tax reflects the company's earnings after accounting for operating expenses, interest, taxes and other applicable items.

Financial Year

Profit After Tax

FY24

₹156.10 crore

FY25

₹249.60 crore

FY26

₹436.70 crore

The company reported higher profit in FY25 and FY26 compared with FY24. Sustaining profitability as the business grows will be an important factor for investors to monitor in the coming years.


Encube Ethicals Financial Summary

Particulars

FY24

FY25

FY26

Revenue

₹1,085.90 Cr

₹1,344.80 Cr

₹1,848.70 Cr

EBITDA

₹297.60 Cr

₹452.10 Cr

₹663.30 Cr

EBITDA Margin

27.41%

33.62%

35.88%

PAT

₹156.10 Cr

₹249.60 Cr

₹436.70 Cr

Net Worth

₹1,258.40 Cr

₹1,512.80 Cr

₹1,953.60 Cr

Total Borrowings

₹228.10 Cr

₹230.50 Cr

₹221.70 Cr

Operating Cash Flow

₹181.90 Cr

₹299.80 Cr

₹303.10 Cr

The financial figures indicate that Encube Ethicals has expanded its revenue base and improved its reported profitability over the period. However, financial growth alone does not determine whether an IPO is attractively priced. The final valuation and issue price will also be important when assessing the offering.


Encube Ethicals IPO GMP Today

As of November 18, 2026, the official IPO price band has not been announced.

The Grey Market Premium (GMP) is an unofficial indicator based on grey-market trading activity before an IPO listing. It is not issued or confirmed by the company, SEBI or the stock exchanges.

Since Encube Ethicals has not announced its final price band or subscription dates, investors should be cautious about relying on speculative GMP figures circulating online.

Encube Ethicals IPO GMP Details

Particulars

Details

IPO Name

Encube Ethicals IPO

GMP Today

Not officially available

IPO Price Band

Not announced

Expected Listing Price

Not available

Estimated Listing Gain

Cannot be calculated

IPO Opening Date

Not announced

IPO Closing Date

Not announced

Listing Date

Not announced

SEBI Observations

Received

IPO Status

Awaiting final issue schedule

GMP is unofficial, can change rapidly and should not be considered a reliable indicator of listing performance.


Encube Ethicals IPO Business Strengths

Encube Ethicals operates in a pharmaceutical segment where manufacturing capabilities, product quality, regulatory compliance and customer relationships are important. Some of the company's business strengths that investors may evaluate include the following.

1. Specialised Pharmaceutical Manufacturing

The company focuses on topical and transdermal formulations, which require specialised manufacturing processes and technical expertise. Its focus on these product categories may help it build capabilities and relationships with pharmaceutical customers.

2. International Business Presence

Encube has business exposure to international pharmaceutical markets. Selling into multiple countries can provide opportunities for growth beyond the domestic market, although international operations also involve regulatory and market-specific requirements.

3. CDMO Business Opportunity

The contract development and manufacturing business allows Encube to serve other pharmaceutical companies. Outsourcing manufacturing can create opportunities for specialised pharmaceutical companies as clients seek manufacturing partners with appropriate capabilities and regulatory compliance systems.

4. Growing Revenue and Profitability

The company has reported growth in revenue, EBITDA and profit after tax across FY24, FY25 and FY26. Continued financial growth could support its business development if it is sustained.

5. Established Operating Experience

Encube has been operating since 1995 and has developed pharmaceutical manufacturing and formulation capabilities over the years. Its experience in the industry may support its operations, product development and relationships with customers.


Risks Investors Should Consider Before Investing in Encube Ethicals IPO

Despite its business strengths, investors should carefully evaluate the risks disclosed in the company's offer documents.

1. Regulatory and Compliance Risk

Pharmaceutical manufacturing is subject to strict regulatory requirements. Changes in regulations, manufacturing compliance issues, quality concerns or delays in approvals may affect the company's operations and financial performance.

2. Customer Concentration Risk

If a significant portion of revenue comes from a limited number of customers, the loss of a major customer or a reduction in orders could impact revenue and profitability.

3. Export Market Risk

Encube's international business exposes it to foreign regulatory requirements, exchange-rate movements, changing market conditions and competition in overseas pharmaceutical markets.

4. Manufacturing and Quality Risks

Pharmaceutical companies must maintain consistent product quality and manufacturing standards. Product recalls, manufacturing disruptions, regulatory observations or quality-related issues could affect business operations and reputation.

5. IPO Valuation Risk

The company's financial performance may be improving, but the valuation at which shares are offered will determine whether the IPO provides an attractive investment opportunity.

Investors should compare the final valuation with the company's earnings, growth prospects, margins, debt, cash flow and listed pharmaceutical peers before making a decision.

6. OFS-Only IPO Structure

The proposed IPO consists entirely of an Offer for Sale. Since no fresh shares are being issued to raise capital, the company will not receive the IPO proceeds for its business expansion.

This makes it important for investors to understand why existing shareholders are selling their holdings and how the proposed offer may affect the company's shareholding structure after listing.


Encube Ethicals IPO Valuation and Peer Comparison

The valuation of Encube Ethicals will become clearer once the company announces its IPO price band and final offer details. Until then, investors cannot accurately calculate the IPO's price-to-earnings (P/E) ratio or determine whether the issue is priced attractively.

Encube operates in the pharmaceutical manufacturing and CDMO space. Investors may compare the company with other pharmaceutical manufacturers, contract manufacturing companies and speciality formulation businesses.

Some of the factors that can help in valuation analysis include:

  • Revenue growth over the last three financial years
  • EBITDA margin and operating profitability
  • Profit after tax and earnings per share
  • Return on net worth
  • Debt and cash flow position
  • Pharmaceutical manufacturing capabilities
  • International business exposure
  • Customer concentration
  • Valuation of listed pharmaceutical and CDMO peers

The final IPO valuation should be evaluated against these factors rather than relying only on the company's growth rate or market interest in the issue.


Encube Ethicals IPO Listing Date and Expected Listing Price

Encube Ethicals has received SEBI observations on its draft IPO documents, but the company has not yet officially announced its IPO opening date, closing date or listing date as of November 18, 2026.

The proposed IPO is expected to be listed on the NSE and BSE, subject to the final issue documents and listing approvals.


Expected Listing Price

The expected listing price of Encube Ethicals shares cannot currently be estimated reliably because the IPO price band has not been announced.

The eventual listing price will depend on several factors, including the final IPO price, investor demand during the subscription period, subscription levels across investor categories, market conditions on the listing day, the company's financial performance, the valuation assigned to the company and overall sentiment towards pharmaceutical stocks.

Investors should avoid treating unofficial GMP figures or expected listing gains as guaranteed returns.


Should You Invest in Encube Ethicals IPO?

Encube Ethicals may be worth evaluating for investors interested in pharmaceutical manufacturing, speciality formulations and the CDMO industry. The company's revenue growth, improving profitability and established manufacturing business provide important points for further analysis.

However, investment decisions should not be based on financial growth alone.

Before applying for the IPO, investors should carefully review the final RHP, particularly the valuation, financial statements, risk factors, customer concentration, regulatory disclosures, promoter shareholding and the proposed OFS structure.

Since the IPO is entirely an Offer for Sale, the company will not receive funds from the public issue. Investors should therefore understand the company's existing financial position and future business plans independently of the IPO fundraising.

Whether the IPO is attractive will ultimately depend on the price at which the shares are offered and the company's ability to maintain its growth and profitability.



Conclusion

The Encube Ethicals IPO is a proposed ₹3,000 crore public offering that will allow existing shareholders to sell part of their stake in the pharmaceutical manufacturing company. The company operates in topical and transdermal formulations, generic medicines, contract manufacturing and branded pharmaceutical products.

Encube's financial performance has improved across FY24, FY25 and FY26, with revenue, EBITDA and profit after tax showing growth. Its pharmaceutical manufacturing capabilities and exposure to international markets may provide opportunities for future business development.

However, investors should also consider regulatory risks, competition, customer concentration, manufacturing requirements and the OFS-only nature of the IPO. The final price band and valuation will be particularly important in determining whether the issue is worth considering.

As of November 18, 2026, SEBI observations have been received, but the IPO price band, opening date, lot size and listing schedule have not yet been officially announced. Investors should wait for the final offer documents and make decisions based on the company's fundamentals, valuation and personal risk tolerance.